And just to clarify my earlier post, i think B for ABSSSI results alone can take the SP that far, ignoring the 800lb gorilla in the room, or any bumps from Prurisol catalysts. Most young biotechs would love to have a compound as promising as Brilacidin as their flagship drug. I'd say it is a pretty nice compliment to the monster that Kevetrin will become.
By the end of this year, comprehensive clinical trial results from Kevetrin P1 and brilacidin 2B will leave this company fundamentally transformed, from both a business and a stock price perspective.
Thanks for your kind words, just calling it as I genuinely see it. The real verdict will come at trial's end. :-)
Market Data 
Markets 
AI
